Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05595369 · ClinicalTrials.gov registry record · Phase 2
RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms
A Phase 2 study, sponsored by Kanecia Obie Zimmerman.
- Completed
- Registry status
- Phase 2
- Development phase
- 963
- Enrollment target
NCT05595369 is a Phase 2 study that has completed, run by Kanecia Obie Zimmerman. The registered enrollment target is 963 participants.
The verdict
NCT05595369, a Phase 2 study, has completed, sponsored by Kanecia Obie Zimmerman.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 963 participants
- Enrollment target
Study Summary
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, double-blind, randomized, controlled platform trial with different interventions organized as appendices to the protocol. Each appendix (or sub-study) evaluates potential mechanisms of action, efficacy, and safety of antivirals and other therapeutics in individuals with PASC, according to the platform protocol objectives. The hypothesis is that persistent viral infection, viral reactivation, and/or overactive/chronic immune response and inflammation are underlying contributors to PASC and that antiviral and other applicable therapies may result in viral clearance or decreased inflammation and improvement in PASC symptoms.
Interventions
- DRUG Experimental: Paxlovid 25 day dosing
- DRUG Experimental: Paxlovid 15 day dosing
- DRUG Placebo Comparator: Control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 963 participants |
| Start Date | 2023-07-26 |
| Est. Completion | 2025-03-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05595369
The ClinicalTrials.gov registry entry for NCT05595369 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 963 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kanecia Obie Zimmerman, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Experimental: Paxlovid 25 day dosing is the first listed.
NCT05595369 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05595369 about?
NCT05595369 is a clinical study titled "RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms". This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm...
What is the current status of trial NCT05595369?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 963 participants. The study started on 2023-07-26. Estimated completion is 2025-03-13.
What interventions are being tested in trial NCT05595369?
The interventions under investigation include: Experimental: Paxlovid 25 day dosing (DRUG), Experimental: Paxlovid 15 day dosing (DRUG), Placebo Comparator: Control (DRUG).
Who is sponsoring clinical trial NCT05595369?
This trial is sponsored by Kanecia Obie Zimmerman, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.